Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies
نویسندگان
چکیده
منابع مشابه
Monoclonal antibodies targeting CD20
We are commenting on the article by Klein et al. on the functional properties of several anti-CD20 monoclonal antibodies (mAbs) in the January/February 2013 issue of mAbs. 1 Rituximab, the first monoclonal antibody approved for cancer therapy, has truly revolutionized the treatment of a variety of CD20 + hema-tological malignancies, 2,3 and also has been studied in a large number of autoimmune ...
متن کاملEffector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies.
Activation of the complement system by tumor cells was long believed to only benefit the host. Overexpression of complement inhibitors by many tumor cell types and results obtained in several experimental animal models were all in agreement with this hypothesis. However, recent reports imply that the situation is more complex than initially believed and that under certain circumstances tumor ce...
متن کاملAnti-CD20 monoclonal antibodies: historical and future perspectives.
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates f...
متن کاملAntigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.
Following the success of rituximab, 2 other anti-CD20 monoclonal antibodies (mAbs), ofatumumab and obinutuzumab, have entered clinical use. Ofatumumab has enhanced capacity for complement-dependent cytotoxicity, whereas obinutuzumab, a type II mAb, lacks the ability to redistribute into lipid rafts and is glycoengineered for augmented antibody-dependent cellular cytotoxicity (ADCC). We previous...
متن کاملMolecular mechanisms of the antitumor effects of anti-CD20 antibodies.
Anti-CD20 monoclonal antibodies (mAbs) have become the mainstay in the treatment of non-Hodgkin's lymphomas and have shown significant activity in patients with B-cell chronic lymphocytic leukemia. Antitumor action of these antibodies results from triggering of indirect effector mechanisms of the immune system that include activation of complement-dependent cytotoxicity (CDC), antibody-dependen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Opinion in Immunology
سال: 2008
ISSN: 0952-7915
DOI: 10.1016/j.coi.2008.05.011